Placebo Control

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical tr...

One of the unintended consequences of my (admittedly, somewhat impulsive) decision to name this blog is that I get a fair bit of traffic fr...

I have a lot of respect for Eric Topol, and am a huge fan of his ongoing work  to bring new mobile technology to benefit patients. The ...

Not to be confused with the Test Act . (via Luminarium) 4 Democratic members of Congress recently co-sponsored the TEST (Trial and Expe...

If you’re a human being, in possession of one working, standard-issue human brain (and, for the remainder of this post, I’m going to assume ...

Following up on yesterday's post regarding a study of placebo-related information, it seems worthwhile to pause and expand on the diffe...

At the end of last year, US Reps Cliff Stearns (R-FL) and Ed Towns (D-NY) introduced the Unlocking Lifesaving Treatments for Rare-Diseases A...

The FDA Law Blog has an incredibly interesting entry regarding last week's Untitled Letter from the FDA's Division of Drug Marketin...

No matter what, negative clinical trial results are sad. We can appreciate, intellectually, that clinical equipoise is important and that ne...

I don’t think this qualifies yet as a trend, but two disturbing announcements came right back to back last week: First: As you’ve probably h...

Euthymics , a small Massachusetts-based biotech, recently announced the start of the TRIADE trial , which they describe as “Phase 2b/3a”. I...